Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Saturday.
Other research analysts have also issued reports about the company. Leerink Swann started coverage on Adaptimmune Therapeutics in a research report on Friday. They issued a “buy” rating and a $15.00 target price on the stock. ValuEngine lowered Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics presently has an average rating of “Hold” and a consensus target price of $11.58.
Adaptimmune Therapeutics (NASDAQ:ADAP) opened at $11.06 on Friday. Adaptimmune Therapeutics has a 52-week low of $3.90 and a 52-week high of $13.41. The firm has a market capitalization of $1,024.94, a PE ratio of -13.33 and a beta of 1.79.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3270741/bidaskclub-upgrades-adaptimmune-therapeutics-adap-to-sell.html.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.